Literature DB >> 17706607

In vitro screening strategies for nicotinic receptor ligands.

John Dunlop1, Renza Roncarati, Brian Jow, Hendrick Bothmann, Tim Lock, Dianne Kowal, Mark Bowlby, Georg C Terstappen.   

Abstract

A common historical strategy to the discovery of nicotinic receptor ligands has involved the use of radioligand-binding assays for ligand identification in combination with two-electrode voltage clamp in Xenopus oocytes for electrophysiological characterization. More recently, higher-throughput methodologies have replaced these approaches to accommodate screening of large compound libraries and to provide increased capacity for electrophysiological profiling in mammalian cell lines. We, and others, have implemented cell-based screening assays using the fluorometric imaging plate reader (FLIPR) for primary and lead optimization screening of nicotinic receptor agonists and positive allosteric modulators (PAMs). Using GH4C1 cells expressing the rat alpha7 nicotinic receptor, both acetylcholine and nicotine produced concentration-dependent elevations of intracellular calcium with EC(50) values of 5.5 and 1.6 microM, respectively. PAM activity was robustly detected using the FLIPR assay; for example, the known alpha7 receptor PAM 5-hydroxyindole failed to directly activate the receptor but produced a leftward shift of the nicotine concentration-response curve in combination with a potentiation of the maximum evoked response to nicotine. Electrophysiological confirmation of agonist activity was achieved using the Dynaflow rapid perfusion system and patch clamp in the same GH4C1 cell expression system. Estimated EC(50) values for acetylcholine-evoked currents in GH4C1/alpha7 cells were 55 and 576 microM for area-under-the-curve (AUC) and maximum peak height calculations, respectively. Similarly, PAM activity was confirmed using electrophysiological recordings while also allowing for the mechanistic discrimination of compounds, not possible using the FLIPR assay. Specifically, PAMs capable of slowing the rapid desensitization of alpha7 receptors to different extents were discernable in these studies. Further improvements in the capacity to screen compounds using electrophysiology has been achieved by implementation of high-throughput gigaohm quality recording systems such as the QPatch and PatchXpress where agonist EC(50) values are highly comparable to those obtained using conventional manual patch clamp.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706607     DOI: 10.1016/j.bcp.2007.07.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

2.  Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.

Authors:  Clark A Briggs; Jens Halvard Grønlien; Peter Curzon; Daniel B Timmermann; Hilde Ween; Kirsten Thorin-Hagene; Paige Kerr; David J Anderson; John Malysz; Tino Dyhring; Gunnar M Olsen; Dan Peters; William H Bunnelle; Murali Gopalakrishnan
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

Review 3.  Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia.

Authors:  Damian C Bell; Mark L Dallas
Journal:  Br J Pharmacol       Date:  2017-07-18       Impact factor: 8.739

Review 4.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

5.  Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists.

Authors:  Matthew D Hill; Haiquan Fang; H Dalton King; Christiana I Iwuagwu; Ivar M McDonald; James Cook; F Christopher Zusi; Robert A Mate; Ronald J Knox; Debra Post-Munson; Amy Easton; Regina Miller; Kimberley Lentz; Wendy Clarke; Yulia Benitex; Nicholas Lodge; Robert Zaczek; Rex Denton; Daniel Morgan; Linda Bristow; John E Macor; Richard Olson
Journal:  ACS Med Chem Lett       Date:  2016-12-01       Impact factor: 4.345

Review 6.  High throughput electrophysiology with Xenopus oocytes.

Authors:  Roger L Papke; Cathy Smith-Maxwell
Journal:  Comb Chem High Throughput Screen       Date:  2009-01       Impact factor: 1.339

7.  Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795.

Authors:  Gretchen Y López-Hernández; Jeffrey S Thinschmidt; Philippe Morain; Caryn Trocme-Thibierge; William R Kem; Ferenc Soti; Roger L Papke
Journal:  Neuropharmacology       Date:  2009-03       Impact factor: 5.250

8.  Electrophysiology-Based Assays to Detect Subtype-Selective Modulation of Human Nicotinic Acetylcholine Receptors.

Authors:  Glenn E Kirsch; Nikolai B Fedorov; Yuri A Kuryshev; Zhiqi Liu; Lucas C Armstrong; Michael S Orr
Journal:  Assay Drug Dev Technol       Date:  2016-08       Impact factor: 1.738

9.  Characterizing ligand-gated ion channel receptors with genetically encoded Ca2++ sensors.

Authors:  John G Yamauchi; Ákos Nemecz; Quoc Thang Nguyen; Arnaud Muller; Lee F Schroeder; Todd T Talley; Jon Lindstrom; David Kleinfeld; Palmer Taylor
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

10.  Chemical chaperones exceed the chaperone effects of RIC-3 in promoting assembly of functional α7 AChRs.

Authors:  Alexander Kuryatov; Jayanta Mukherjee; Jon Lindstrom
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.